tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ohata K et al. | Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. | 2011 | Biol. Blood Marrow Transplant. | pmid:20736080 |
| Kolb M et al. | Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:26880117 |
| Koreth J et al. | A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. | 2015 | Biol. Blood Marrow Transplant. | pmid:26055298 |
| Kennedy-Nasser AA et al. | Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. | 2006 | Biol. Blood Marrow Transplant. | pmid:17162209 |
| Kusumi E et al. | Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. | 2006 | Biol. Blood Marrow Transplant. | pmid:17162212 |
| Chen YB et al. | Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. | 2015 | Biol. Blood Marrow Transplant. | pmid:26009261 |
| Ho VT et al. | Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. | 2009 | Biol. Blood Marrow Transplant. | pmid:19539216 |
| Osunkwo I et al. | A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. | 2004 | Biol. Blood Marrow Transplant. | pmid:15077223 |
| Yahng SA et al. | A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. | 2015 | Biol. Blood Marrow Transplant. | pmid:25300871 |
| Horowitz MM et al. | Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. | 1999 | Biol. Blood Marrow Transplant. | pmid:10392964 |
| Cutler C et al. | Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. | 2005 | Biol. Blood Marrow Transplant. | pmid:15846292 |
| Tomblyn MR et al. | Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. | 2011 | Biol. Blood Marrow Transplant. | pmid:21073974 |
| Openshaw H | Peripheral neuropathy after bone marrow transplantation. | 1997 | Biol. Blood Marrow Transplant. | pmid:9360782 |
| Baird K et al. | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. | 2015 | Biol. Blood Marrow Transplant. | pmid:25771402 |
| Yagasaki H et al. | Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. | 2009 | Biol. Blood Marrow Transplant. | pmid:19896085 |
| Vasu S et al. | Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. | 2016 | Biol. Blood Marrow Transplant. | pmid:26743340 |
| Satwani P et al. | A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. | 2012 | Biol. Blood Marrow Transplant. | pmid:22079471 |
| Sabry W et al. | Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. | 2009 | Biol. Blood Marrow Transplant. | pmid:19589481 |
| Burroughs LM et al. | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. | 2014 | Biol. Blood Marrow Transplant. | pmid:25196857 |
| Pavletic S and Vogelsand GB | Treatment of high-risk chronic GVHD. | 2008 | Biol. Blood Marrow Transplant. | pmid:19041069 |
| Piñana JL et al. | A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. | 2017 | Biol. Blood Marrow Transplant. | pmid:28396159 |
| Rosenbeck LL et al. | Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. | 2011 | Biol. Blood Marrow Transplant. | pmid:20932925 |
| Oran B et al. | Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. | 2007 | Biol. Blood Marrow Transplant. | pmid:17382253 |
| Cutler C et al. | Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. | 2004 | Biol. Blood Marrow Transplant. | pmid:15111932 |
| Ram R et al. | Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. | 2012 | Biol. Blood Marrow Transplant. | pmid:21875504 |
| Leather H et al. | Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. | 2006 | Biol. Blood Marrow Transplant. | pmid:16503502 |
| Grossman J et al. | Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. | 2014 | Biol. Blood Marrow Transplant. | pmid:25111582 |
| Luznik L et al. | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. | 2008 | Biol. Blood Marrow Transplant. | pmid:18489989 |
| Snyder DS et al. | Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. | 2010 | Biol. Blood Marrow Transplant. | pmid:19786111 |
| Hamilton BK and Kalaycio M | Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis. | 2014 | Biol. Blood Marrow Transplant. | pmid:25065905 |
| Shayani S et al. | Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. | 2013 | Biol. Blood Marrow Transplant. | pmid:23078784 |
| Nieto Y et al. | Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. | 2006 | Biol. Blood Marrow Transplant. | pmid:16443519 |
| Uberti JP et al. | Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. | 2005 | Biol. Blood Marrow Transplant. | pmid:16125638 |
| Kumar AJ et al. | Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. | 2013 | Biol. Blood Marrow Transplant. | pmid:23635453 |
| Miyakoshi S et al. | Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. | 2007 | Biol. Blood Marrow Transplant. | pmid:17580255 |
| Al-Kadhimi Z et al. | Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. | 2012 | Biol. Blood Marrow Transplant. | pmid:22710143 |
| Przepiorka D et al. | Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. | 1999 | Biol. Blood Marrow Transplant. | pmid:10371361 |
| Przepiorka D et al. | Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. | 2000 | Biol. Blood Marrow Transplant. | pmid:10816027 |
| Cuellar-Rodriguez J et al. | Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. | 2015 | Biol. Blood Marrow Transplant. | pmid:25636378 |
| Ogawa H et al. | Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. | 2006 | Biol. Blood Marrow Transplant. | pmid:17084371 |
| Khaled SK et al. | Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:26325438 |
| Satwani P et al. | Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. | 2011 | Biol. Blood Marrow Transplant. | pmid:21338706 |
| Inamoto Y et al. | A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. | 2011 | Biol. Blood Marrow Transplant. | pmid:21421070 |
| Offer K et al. | Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. | 2015 | Biol. Blood Marrow Transplant. | pmid:25536217 |
| Aldoss I et al. | Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:27044907 |
| Furlong T et al. | Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. | 2008 | Biol. Blood Marrow Transplant. | pmid:18410895 |
| Small TN et al. | Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. | 2007 | Biol. Blood Marrow Transplant. | pmid:17241929 |
| Gladstone DE et al. | Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. | 2013 | Biol. Blood Marrow Transplant. | pmid:23353119 |
| Socié G | Graft-versus-host disease prophylaxis: does drug dosage matter? | 2012 | Biol. Blood Marrow Transplant. | pmid:22200648 |
| Moiseev IS et al. | Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. | 2016 | Biol. Blood Marrow Transplant. | pmid:26970381 |
| Hamadani M et al. | Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. | 2009 | Biol. Blood Marrow Transplant. | pmid:19822302 |
| Inamoto Y et al. | Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. | 2015 | Biol. Blood Marrow Transplant. | pmid:26033280 |
| Cheng C et al. | MARD: a new method to detect differential gene expression in treatment-control time courses. | 2006 | Bioinformatics | pmid:16928738 |
| Quesniaux VF | Immunosuppressants: tools to investigate the physiological role of cytokines. | 1993 | Bioessays | pmid:7507316 |
| DaSilva I et al. | Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain. | 2017 | BioDrugs | pmid:28534103 |
| Keating GM and Lyseng-Williamson KA | Everolimus: a guide to its use in liver transplantation. | 2013 | BioDrugs | pmid:23696253 |
| Patel JK and Kobashigawa JA | Tacrolimus in heart transplant recipients: an overview. | 2007 | BioDrugs | pmid:17516709 |
| Zhai J et al. | Tacrolimus in the treatment of ocular diseases. | 2011 | BioDrugs | pmid:21443273 |
| Allen C et al. | Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. | 1998 Sep-Oct | Bioconjug. Chem. | pmid:9736490 |
| Tamura T et al. | A quantitative analysis and chemical approach for the reduction of nonspecific binding proteins on affinity resins. | 2003 Nov-Dec | Bioconjug. Chem. | pmid:14624639 |
| Cen J et al. | The new immunosuppressant, isogarcinol, binds directly to its target enzyme calcineurin, unlike cyclosporin A and tacrolimus. | 2015 | Biochimie | pmid:25701551 |
| Shadidy M et al. | Biochemical analysis of mouse FKBP60, a novel member of the FKPB family. | 1999 | Biochim. Biophys. Acta | pmid:10524204 |
| Raufman JP et al. | Regulation of calcium-induced exocytosis from gastric chief cells by protein phosphatase-2B (calcineurin). | 1997 | Biochim. Biophys. Acta | pmid:9202177 |
| Karlsson H et al. | Energy levels in resting and mitogen-stimulated human lymphocytes during treatment with FK506 or cyclosporin A in vitro. | 1997 | Biochim. Biophys. Acta | pmid:9131051 |
| Chen Z et al. | Mutations adjacent to the end of transmembrane helices 6 and 7 independently affect drug efflux capacity of yeast ABC transporter Pdr5p. | 2014 | Biochim. Biophys. Acta | pmid:24333836 |
| Faralli JA et al. | Dexamethasone increases αvβ3 integrin expression and affinity through a calcineurin/NFAT pathway. | 2013 | Biochim. Biophys. Acta | pmid:24100160 |
| Ozawa T | Elucidation of the ryanodine-sensitive Ca2+ release mechanism of rat pancreatic acinar cells: modulation by cyclic ADP-ribose and FK506. | 2004 | Biochim. Biophys. Acta | pmid:15363629 |
| Hendrych T et al. | Characterization of the kinetics and mechanisms of inhibition of drugs interacting with the S. cerevisiae multidrug resistance pumps Pdr5p and Snq2p. | 2009 | Biochim. Biophys. Acta | pmid:19111673 |
| Stasik I et al. | Ionomycin-induced apoptosis of thymocytes is independent of Nur77 NBRE or NurRE binding, but is accompanied by Nur77 mitochondrial targeting. | 2007 | Biochim. Biophys. Acta | pmid:17588685 |
| Yu L and Fesik SW | pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands. | 1994 | Biochim. Biophys. Acta | pmid:7524680 |
| López E et al. | FKBP52 is involved in the regulation of SOCE channels in the human platelets and MEG 01 cells. | 2013 | Biochim. Biophys. Acta | pmid:23228564 |
| Miyamoto S et al. | Signal transduction pathways that contribute to increased protein synthesis during T-cell activation. | 2000 | Biochim. Biophys. Acta | pmid:11072066 |
| Swartz DJ et al. | P-glycoprotein is fully active after multiple tryptophan substitutions. | 2013 | Biochim. Biophys. Acta | pmid:23261390 |
| Ãœnal CM and Steinert M | FKBPs in bacterial infections. | 2015 | Biochim. Biophys. Acta | pmid:25529296 |
| Poirier SN et al. | FK506 blocks intracellular Ca2+ oscillations in bovine adrenal glomerulosa cells. | 2001 | Biochemistry | pmid:11371212 |
| Galat A et al. | A rapamycin-selective 25-kDa immunophilin. | 1992 | Biochemistry | pmid:1371698 |
| Kueppers P et al. | Functional impact of a single mutation within the transmembrane domain of the multidrug ABC transporter Pdr5. | 2013 | Biochemistry | pmid:23464591 |
| Liu J et al. | Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. | 1992 | Biochemistry | pmid:1373650 |
| Harrison RK and Stein RL | Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. | 1990 | Biochemistry | pmid:1693856 |
| Gatto GJ et al. | Elucidating the substrate specificity and condensation domain activity of FkbP, the FK520 pipecolate-incorporating enzyme. | 2005 | Biochemistry | pmid:15835888 |
| Yem AW et al. | An active FK506-binding domain of 17,000 daltons is isolated following limited proteolysis of chicken thymus hsp56. | 1993 | Biochemistry | pmid:7504525 |
| Furutani M et al. | FK506 binding protein from a thermophilic archaeon, Methanococcus thermolithotrophicus, has chaperone-like activity in vitro. | 2000 | Biochemistry | pmid:10631007 |
| Fischer S et al. | A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). | 1993 | Biochemistry | pmid:7505615 |
| Kotaka M et al. | Crystal structure of the FK506 binding domain of Plasmodium falciparum FKBP35 in complex with FK506. | 2008 | Biochemistry | pmid:18465874 |
| Hutchison KA et al. | FK506 binding to the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. | 1993 | Biochemistry | pmid:7682438 |
| Craescu CT et al. | Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. | 1996 | Biochemistry | pmid:8780506 |
| Jana B et al. | Domain structure and denaturation of a dimeric Mip-like peptidyl-prolyl cis-trans isomerase from Escherichia coli. | 2012 | Biochemistry | pmid:22263615 |
| Yang CJ et al. | Differential Large-Amplitude Breathing Motions in the Interface of FKBP12-Drug Complexes. | 2015 | Biochemistry | pmid:26561008 |
| Connelly PR et al. | Probing hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and rapamycin binding to FK506 binding protein in D2O and H2O. | 1993 | Biochemistry | pmid:7684925 |
| Mondragon A et al. | Overexpression and purification of human calcineurin alpha from Escherichia coli and assessment of catalytic functions of residues surrounding the binuclear metal center. | 1997 | Biochemistry | pmid:9125515 |
| Weiwad M et al. | Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. | 2006 | Biochemistry | pmid:17176100 |
| Linnert M et al. | The FKBP-type domain of the human aryl hydrocarbon receptor-interacting protein reveals an unusual Hsp90 interaction. | 2013 | Biochemistry | pmid:23418784 |
| Rosen MK et al. | Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. | 1991 | Biochemistry | pmid:1709363 |
| Solomentsev G et al. | Conformational Entropy of FK506 Binding to FKBP12 Determined by Nuclear Magnetic Resonance Relaxation and Molecular Dynamics Simulations. | 2018 | Biochemistry | pmid:29412644 |
| Cañadas O et al. | Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. | 2004 | Biochemistry | pmid:15274647 |
| Lepre CA et al. | Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12. | 1994 | Biochemistry | pmid:7524662 |
| Tai PK et al. | P59 (FK506 binding protein 59) interaction with heat shock proteins is highly conserved and may involve proteins other than steroid receptors. | 1993 | Biochemistry | pmid:7689858 |
| Cheng JW et al. | 15N NMR relaxation studies of the FK506 binding protein: backbone dynamics of the uncomplexed receptor. | 1993 | Biochemistry | pmid:7690248 |
| DiLella AG and Craig RJ | Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. | 1991 | Biochemistry | pmid:1716149 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |